For decades, there was no treatment that stopped keratoconus from getting worse. Glasses could partially correct it. Rigid gas permeable contacts could mask it. Scleral lenses could vault over it. But the cornea kept thinning, kept steepening, kept distorting. Patients watched their prescriptions change every 6–12 months and waited for the disease to stabilize on its own — which it sometimes did, and sometimes didn’t.
The FDA approved corneal cross-linking (CXL) in 2016 — the first and, as of 2025, the only treatment proven to halt keratoconus progression. It’s now the standard of care for progressive keratoconus worldwide. Understanding what it costs, what insurance covers, and what happens if you delay is essential for anyone navigating this diagnosis.
What Corneal Cross-Linking Does
CXL works by creating new molecular bonds within the corneal stroma — the structural layer of the cornea — that stiffen and stabilize the tissue. The procedure combines riboflavin (vitamin B2) eye drops with low-intensity UV-A light. Riboflavin, saturated into the cornea, absorbs the UV energy and initiates a photochemical reaction that crosslinks collagen fibers. More crosslinks mean a stiffer, more structurally stable cornea that resists further thinning.
It doesn’t reverse damage that’s already occurred. It doesn’t flatten a cornea that has already steepened. It stops the clock.
Epithelium-Off vs. Epithelium-On: The Key Decision
There are two main CXL approaches, and they have meaningfully different evidence bases:
Epithelium-off (standard CXL / Dresden protocol): The corneal epithelium — the outermost cell layer — is removed mechanically or with alcohol to allow full riboflavin penetration into the stroma. This is the approach used in the pivotal Avedro iLink FDA approval studies. It’s the most effective method and the gold standard with the longest outcomes data. Recovery takes 3–5 days as the epithelium regenerates; there’s significant discomfort during that window.
Epithelium-on (transepithelial / “epi-on” CXL): The epithelium is left intact, and riboflavin is modified to penetrate through it. Recovery is faster and more comfortable. But the evidence for efficacy is considerably weaker — penetration is less complete, crosslinking depth is shallower, and outcomes data is more limited. Some corneal specialists offer epi-on; many don’t, because the standard epi-off protocol has superior long-term evidence.
| Procedure | Cost Per Eye | Both Eyes | Insurance Status |
|---|---|---|---|
| Epithelium-off CXL (standard) | $2,500–$4,000 | $5,000–$8,000 | Covered by most commercial plans with documentation |
| Epithelium-on CXL (transepithelial) | $2,000–$3,500 | $4,000–$7,000 | Less consistently covered; considered by some plans as less proven |
| CXL with simultaneous topo-guided PRK | $3,500–$5,500 | $7,000–$11,000 | PRK portion typically not covered |
| Corneal transplant (if progression not halted) | $8,000–$15,000 | $16,000–$30,000 | Covered when medically necessary |
Who Needs CXL
Not every keratoconus patient needs CXL. The procedure is indicated specifically for progressive keratoconus — evidence that the cornea is actively worsening. That means:
- Two corneal topography maps (Pentacam, Orbscan, or similar) taken 3–6 months apart showing measurable change in curvature, thickness, or HOA values
- Patient age typically under 40 (keratoconus most commonly stabilizes naturally in the 30s–40s — treating stable disease in a 45-year-old has limited benefit)
- Adequate corneal thickness (generally >400 microns at thinnest point, to ensure UV-A energy doesn’t damage the endothelium)
If your keratoconus is diagnosed but stable, monitoring every 6–12 months with topography is appropriate. CXL becomes urgent when you see change on serial topography.
To get CXL covered by commercial insurance, your corneal specialist needs to submit documentation showing: (1) keratoconus diagnosis with topography showing steepening or thinning over at least 2 maps, (2) inadequacy of non-surgical correction, and (3) medical necessity rationale. The AAO and ASCRS have established billing codes for CXL that most major commercial insurers now recognize. Bring your previous topography maps — even from prior providers — to your appointment. Multiple data points showing consistent progression over time strengthen the authorization case significantly.
Post-CXL: What to Expect
The first 3–5 days after epi-off CXL are uncomfortable. Expect pain, light sensitivity, and blurred vision as the epithelium regenerates. Most patients return to normal activities in 1–2 weeks. But here’s the part many patients don’t anticipate:
Vision often worsens for 3–6 months after CXL. The cornea swells slightly, the epithelium heals irregularly, and refraction shifts. This is normal and expected — it’s not a sign of failure. Vision then gradually stabilizes. Most patients return to their pre-CXL vision by 6–12 months, and many see modest improvement in corneal curvature over the following 1–2 years.
After CXL, most patients still need scleral lenses, RGP contacts, or specialty soft lenses to achieve good visual acuity. CXL doesn’t eliminate the irregular corneal shape — it prevents it from getting worse.
Finding CXL Providers
CXL should be performed by a corneal specialist — typically an ophthalmologist with fellowship training in cornea and refractive surgery. The Avedro iLink system (now Glaukos) is the FDA-approved device used in the US for standard epi-off CXL. Look for:
- Board certification in ophthalmology with cornea subspecialty training
- ABCRS (American Board of Corneal and Refractive Surgery) certification, if available
- Volume: ask how many CXL procedures the surgeon performs monthly
Be cautious of providers offering CXL as part of an aggressive refractive surgery package that includes simultaneous topo-guided PRK (“CXL plus”). While combined CXL + PRK has supporting literature for select patients, the PRK component is not covered by insurance and adds $1,000–$2,000+ per eye out of pocket. It’s a legitimate option for some — but the decision to add PRK should be made carefully, with full understanding that you’re electing an additional cosmetic-refractive procedure on a compromised cornea. The CXL portion is medically necessary; the PRK portion is elective.
The Cost of Waiting
Keratoconus doesn’t wait. A cornea that changes 0.5D in steepening every 6 months will be dramatically harder to fit in contact lenses 3 years from now than it is today. The CLEK (Collaborative Longitudinal Evaluation of Keratoconus) study, which followed 1,209 keratoconus patients over 8 years, found continuous corneal steepening in a significant portion of participants — with many eventually requiring transplantation.
Corneal transplantation — either penetrating keratoplasty (PKP) or DALK — costs $8,000–$15,000 per eye. It’s covered by medical insurance when medically necessary, but it comes with: 12–18 months recovery, lifetime risk of graft rejection, permanent sutures in some protocols, and the continued need for specialty contact lenses over the transplanted tissue. CXL at $2,500–$4,000, when it prevents that outcome, is not an expensive treatment. It’s a cheap insurance policy.
Frequently Asked Questions
CXL is designed to stop progression — not improve vision. Most patients don't see a significant vision improvement after CXL; some actually experience slightly reduced vision in the 3–6 months following the procedure as the cornea heals and swells. Over the following year, the cornea typically stabilizes, and some patients see modest improvement in corneal curvature. Vision correction after CXL still requires glasses, contacts, or scleral lenses in most cases. The goal is to preserve the cornea you have — not to eliminate the need for optical correction.
Coverage has improved significantly since the FDA approved CXL in 2016. Most major commercial insurers now cover CXL for progressive keratoconus when documented with two topography maps showing measurable change over 3–6 months. Medicare coverage is more variable and plan-dependent. The key is documentation: your provider needs objective topography evidence of progression to get prior authorization. Without documented progression, most plans will deny it as elective. Work with a corneal specialist who is experienced with the insurance documentation process.
Without treatment, progressive keratoconus continues thinning and steepening the cornea. Vision becomes increasingly difficult to correct — even with scleral lenses. In advanced cases, the cornea develops hydrops (acute corneal swelling from Descemet membrane breaks) or thins to the point where contact lenses can no longer be fit safely. The endpoint for many untreated progressive cases is corneal transplantation — a penetrating keratoplasty (PKP) or deep anterior lamellar keratoplasty (DALK) that costs $8,000–$15,000 per eye and carries its own recovery, rejection risk, and lifetime of monitoring.